Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04065269 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no Loss

Study acronym: ATARI
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 20, 2026 (before its estimated August 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Primary and study completion dates: Apr 2026 to Aug 2026
    • Site details revised at 9 of 9 sites
    v7
  2. Enrollment target: 40 to 174v6 Show 7 more changesShow less
    • Primary and study completion dates: Mar 2023 to Apr 2026
    • Study sites: 1 to 9
    • Interventions: AZD6738 (Drug), Olaparib (Drug) to Ceralasertib (Drug), Durvalumab (Drug), Olaparib (Drug)
    • Eligibility criteria expanded, about 808 words
    • Study description expanded, about 53 words
    • Study arms: 4 to 6
    • Study title expanded, about 1 word
  3. Re-verified, no change to tracked fieldsv5
  4. Start date changed from estimate of Nov 2019 to Nov 27, 2019v4
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Sep 2019 to Nov 2019
    • Site details revised
    v3
  6. Secondary endpoints revised (6)v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institute of Cancer Research, United Kingdom
42 trials monitored
See 2 trials at risk
Ovarian Cancer
1,336 trials monitored
See 90 trials at risk
Sarcoma
1,026 trials monitored
See 67 trials at risk
Cervical Cancer
916 trials monitored
See 51 trials at risk
and 1 more disease
ATARI trial tests the ATR inhibitor drug ceralasertib (AZD6738) alone and in combination with either a PARP inhibitor drug called olaparib, or an anti-PD-L1 immunotherapy called durvalumab (MEDI4736) in patients with relapsed gynaecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in the ARID1A gene.
Trial Details
NCT Number NCT04065269
Lead Sponsor Institute of Cancer Research, United Kingdom
Collaborators: Cancer Research UK, AstraZeneca
Conditions
(from sponsor)		 Gynaecological Cancers
Related terms Carcinoma, Endometrioid, Carcinosarcoma, Endometrial Neoplasms, Uterine Cervical Neoplasms
Enrollment 174 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov